UCLA Journal of Radiation Oncology January 1, 2022 - Flipbook - Page 34
UCLA RADIATION ONCOLOGY JOURNAL
of people with the KRAS-variant better fight
their cancer.
HPV, the most common sexually transmitted
infection in the United States, is thought to
cause about 70% of oropharyngeal cancers
in the United States, according to the Centers
for Disease Control and Prevention. This is
increasingly becoming the most commonly
diagnosed cancer of the head and neck.
Chin’s discussion will address current studies
focusing on treatment for this specific
patient population.
DISCLOSURE
Dr. Chin is the principal investigator of an
active prospective clinical trial sponsored
by Eli Lilly: Randomized Phase II Trial of
Radiotherapy with Concurrent Cisplatin
+/- Concurrent Cetuximab for HPV-positive
Oropharyngeal Squamous Cell Carcinoma
(OPSCC) in KRAS-variant Patients.
IMPACT
This and related research at UCLA Jonsson
Comprehensive Cancer Center has provided
evidence that patients with variant KRAS
may have an altered immune system. This
likely explains both elevated cancer risk as
well as benefit from cetuximab for these
individuals. Chin’s discussion will describe
how new insights are being exploited to
identify people who respond differently
to therapies that depend on the immune
response. Additionally, the use of this and
similar biomarkers may be used to design
personalized radiation therapy and immune
therapies for cancer.
SPEAKER/PRESENTER
Dr. Robert Chin is a radiation oncologist
with UCLA Jonsson Comprehensive Cancer
Center.
JOURNAL/MEETING
ASTRO, the annual meeting of the American
Society for Radiation Oncologists, Chicago
Oct. 24-27. Wednesday, October 27 at 11:35
AM
Panel 20 - Molecular Biomarkers and TumorFree DNA in HPV-Associated Oropharyngeal
Cancer and Implications for Future Clinical
Trials. Impact of KRAS variants on patients
with HPV-associated oropharyngeal cancer
PRESENTING AUTHOR: ROBERT K. CHIN,
M.D., PH.D.
34